Introduction {#s1}
============

The highly specialized epithelial cells in the adult pancreas ([@bib52]) derive from common progenitors during embryogenesis ([@bib5]; [@bib19]; [@bib39]). The cells forming the exocrine pancreas, namely acinar, ductal and centroacinar cells, are believed to constitute the likely origin of pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer and one of the deadliest human malignancies (for review, see ([@bib45]; [@bib48]; [@bib53]; [@bib66]). Kras mutations are common in human pancreatic cancer ([@bib4]; [@bib23]; [@bib28]), and are present with high frequency in the precursor lesions to pancreatic cancer known as Pancreatic Intraepithelial Neoplasia (PanIN) ([@bib30]; [@bib33]). Genetically engineered mice that express oncogenic Kras in the pancreas develop PanINs that progress to pancreatic cancer ([@bib1]; [@bib24]; [@bib25]), a process that is accelerated by the introduction of other common mutations, such as mutation or loss of tumor suppressors p53 and Ink4a/ARF ([@bib1]; [@bib25]).

In mice, both ductal and acinar cells can serve as the cell of origin for pancreatic cancer ([@bib14]; [@bib20]; [@bib21]; [@bib58]). However, acini are more susceptible to transformation, through a process of dedifferentiation known as acinar-ductal metaplasia (ADM) ([@bib34]). ADM is a reversible physiological process that protects the pancreas upon tissue injury, such as acute pancreatitis ([@bib22]; [@bib27]; [@bib56]) in part by reducing the production of digestive enzymes. In presence of oncogenic Kras, pancreatitis-induced ADM becomes irreversible and progresses to PanIN lesions ([@bib6]; [@bib20]). We have previously described the iKras\* mouse model, which allows inducible and reversible expression of oncogenic Kras upon administration of doxycycline (DOX) ([@bib8]). By inactivating oncogenic Kras at different stages of carcinogenesis, we showed that sustained Kras activity is necessary to maintain ADM as well as PanIN lesions, and inactivation of oncogenic Kras leads to redifferentiation of acinar cells ([@bib8]). Kras-driven de-differentiation of the acinar cell compartment is mediated, at least in part, by activation of the Kras effector pathway MAPK/ERK ([@bib10]). Conversely, the acinar cell specific transcription factors PTF1A and BHLHA15, as well as the pancreatic transcription factor PDX1, protect cellular identity and thus counteract transformation ([@bib35]; [@bib50]; [@bib51]).

Epithelial cells within the pancreas exist in the context of a complex microenvironment that rapidly reacts to tissue damage (for review see\[[@bib61]\]). Myeloid cells are an abundant component of the immune infiltrate during the onset of pancreatic carcinogenesis ([@bib7]; [@bib57]). Macrophages and other myeloid subsets are required for PanIN formation ([@bib36]; [@bib63]) and might be sufficient to induce ADM ([@bib36]; [@bib37]). Macrophages are similarly important for pancreas regeneration following acute damage, such as experimental loss of acinar cells ([@bib12]).

While mechanisms regulating acinar cell identity and the regulation of the microenvironment have been addressed separately, we have little understanding of how the cross-talk between different cell types affects these aspects of pancreatic biology. Here, we have set out to study the interactions between pancreatic epithelial cells and infiltrating myeloid cells and determine the effect of oncogenic Kras expression in modulating this interaction.

Results {#s2}
=======

Myeloid cells are required for PanIN maintenance and progression {#s2-1}
----------------------------------------------------------------

To investigate the cross-talk between epithelial cells and myeloid cells, we generated iKras\*;CD11b-DTR mice ([Figure 1A](#fig1){ref-type="fig"}). CD11b-DTR mice express the simian *Diphtheria Toxin Receptor* gene in myeloid cells thus allowing depletion of these cells at will by administration of Diphtheria Toxin (DT) ([@bib16]). To validate myeloid cell depletion in the pancreas, we treated mice with a single dose of Diphtheria Toxin , and the induced acute pancreatitis, a process accompanied by myeloid cell infiltration ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Compared to control, DT injection resulted in a 40--45% decrease of pancreas infiltrating CD11b^+^ cells; we observed similar depletion of macrophages and Myeloid-derived suppressor cells (MDSCs), but little change in the dendritic cell population ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). We then depleted myeloid cells in oncogenic Kras-expressing pancreata, following formation of low-grade PanINs. In brief, doxycycline was added to the drinking water to induce oncogenic Kras\* expression in adult mice. Acute pancreatitis was induced 72 hr later by caerulein administration for two consecutive days to promote PanIN formation as previously described ([@bib8]). A subset of the mice was sacrificed 3 weeks later, while the remaining animals were administered DT and harvested either 3 days or 1 week later ([Figure 1B](#fig1){ref-type="fig"}, n = 5--7 mice/cohort). Histopathological analysis 3 weeks post caerulein revealed low-grade PanINs and ADM surrounded by fibrotic stroma throughout the pancreas parenchyma both in iKras\* and in iKras\*-CD11b mice ([Figure 1C](#fig1){ref-type="fig"}). DT treatment had no effect on lesion progression in iKras\* mice, compared to untreated control. Pancreata from iKras\*-CD11b mice harvested 3 days following DT treatment were histologically indistinguishable from control. In contrast, 1 week following myeloid depletion, we observed occasional acini, increased ADM and fewer mucinous lesions and PanINs than in corresponding iKras\* tissues ([Figure 1C](#fig1){ref-type="fig"}, quantification in [Figure 1D](#fig1){ref-type="fig"}). Furthermore, upon myeloid cell depletion, we observed a reduction in MAPK activation in epithelial cells (as determined by p-ERK1/2 immunostaining) notwithstanding the continuous presence of oncogenic Kras ([Figure 1E](#fig1){ref-type="fig"}). This reduction in MAPK signaling correlated with an increase of acinar differentiation in the tissue, as determined by staining for Basic helix-loop-helix family member a15 (BHLHA15, also known as MIST1) ([Figure 1F](#fig1){ref-type="fig"}) and for Amylase, a digestive enzyme ([Figure 1G](#fig1){ref-type="fig"}). We also observed co-expression of acinar markers (BHLHA15 and Amylase) with the ductal marker CK19, possibly indicating ongoing re-differentiation of acinar cells ([Figure 1F and G](#fig1){ref-type="fig"}). To distinguish between re-differentiation and outgrowth of cells that had escaped recombination, we stained the tissue for EGFP. The *Rosa26* locus in iKras\* mice expresses *rtTa-IRES-EGFP* following Cre recombination ([@bib8]), thus EGFP expression serves as lineage tracing for cells that have undergone recombination and activated oncogenic *Kras* in a rtTa-dependent manner. Our results showed that both PanIN/ADM lesions and recovered acinar cells expressed EGFP, thus validating the redifferentiation of acini from low-grade lesions ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). We also observed a reduction in intracellular mucin, as measured by Periodic Acid--Schiff (PAS) staining ([Figure 2A](#fig2){ref-type="fig"}). We did not observe changes in apoptosis (Cleaved Caspase three staining, [Figure 2B](#fig2){ref-type="fig"}). Immunostaining for the macrophage marker F4/80 confirmed depletion of this cell population in the pancreas ([Figure 2C](#fig2){ref-type="fig"}).

![Myeloid cells are required for PanIN maintenance.\
(**A**) Genetic makeup of the iKras\*;CD11b-DTR mouse model. (**B**) Experimental design, n = 7 mice/cohort. (**C**) H&E staining of iKras\* and iKras\*;CD11b-DTR pancreata 3 weeks post pancreatitis induction and iKras\*;CD11b-DTR pancreata followed by DT treatment for 3 days and 1 week. Scale bar 50 µm. (**D**) Pathological analysis for iKras\* and iKras\*;CD11b-DTR pancreata 1 week following DT treatment. Data represent mean ± SEM, n = 3 mice/cohort. The statistical difference between iKras\* and iKras\*;CD11b-DTR mice per lesion type was determined by Two-tailed unpaired *t*-tests. (**E**) Immunohistochemistry for p-ERK1/2 of iKras\* and iKras\*;CD11b-DTR pancreata. Scale bar 50 µm. (**F**) Co-immunofluorescent staining for BHLHA15 (red), CK19 (green), SMA (magenta) and DAPI (blue); (**G**) Co-immunofluorescent staining for Amylase (red), CK19 (green), SMA (magenta) and DAPI (blue) in iKras\* and iKras\*;CD11b-DTR pancreata 3 weeks post pancreatitis and followed by DT treatment for 1 week. Scale bar 25 µm. Yellow dashed lines indicate epithelial cell clusters co-expressing BHLHA15 and CK19 (**F**) or co-expressing Amylase and CK19 (**G**).\
10.7554/eLife.27388.005Figure 1---source data 1.Histopathological analysis (related to [Figure 1D](#fig1){ref-type="fig"}).](elife-27388-fig1){#fig1}

![Myeloid cell depletion induces PanIN regression and stroma inactivation.\
(**A**) Periodic acid--Schiff (PAS) staining; (**B**) immunohistochemistry staining for Cleaved caspase three and (**C**) F4/80 in iKras\* and iKras\*;CD11b-DTR pancreata 3 week post pancreatitis induction and in iKras\*;CD11b-DTR pancreata following DT treatment for 3 days and 1 week. Scale bar 50 µm. (**D**) qRT-PCR for transgenic *Kras\**, *Fn1*, *Col1a1*, *Col3a1, Shh*, *Hbegf, Ereg, Areg, Tgfα* and *Egf* in littermate control and iKras\*;CD11b-DTR pancreata 3 weeks post pancreatitis and in iKras\*;CD11b-DTR pancreata following DT treatment for 3 days and 1 week. Data represent mean ± SEM, each point indicates one animal. The statistical difference was determined by Two-tailed unpaired *t*-tests. (**E**) Immunohistochemistry staining for p-EGFR in iKras\* and iKras\*;CD11b-DTR pancreata post pancreatitis induction and iKras\*;CD11b-DTR pancreata following DT treatment for 3 days and 1 week. Scale bar 50 µm.](elife-27388-fig2){#fig2}

In parallel with changes in the epithelial compartments, myeloid cell depletion led to changes in the stroma. Although tissue fibrosis was still evident by histology ([Figure 1C](#fig1){ref-type="fig"}), we observed reduced expression of Smooth Muscle Actin (SMA), a fibroblast activation marker ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"} and quantification in [Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). Consistently, the expression of genes for the production of extracellular matrix components, such as *Fibronectin 1 (Fn1)*, *Collagen type I alpha one chain* (*Col1a1*) and *Collagen type III alpha one chain* (*Col3a1*), was reduced ([Figure 2D](#fig2){ref-type="fig"}). *Sonic hedgehog* (*Shh*), secreted by pancreatic neoplastic cells to activate surrounding fibroblasts ([@bib3]; [@bib60]), was similarly reduced upon myeloid cell depletion. Even in presence of oncogenic Kras, ligand-mediated activation of EGFR is required to maintain elevated Kras/MAPK activity ([@bib2]). Given the reduction in MAPK signaling levels, we investigated the expression of EGFR ligands by qRT-PCR. Intriguingly, the expression of the EGFR ligand *Heparin-Binding epidermal-growth-factor (EGF)-like growth factor* (*Hbegf)* −previously shown to promote pancreatic carcinogenesis ([@bib2]; [@bib47])− decreased upon myeloid cell depletion, suggesting that myeloid cells might be a source of this factor or regulate its expression in other compartments ([Figure 2D](#fig2){ref-type="fig"}). We observed a similar pattern for *Epiregulin* (*Ereg*), which decreased upon myeloid cell depletion. In contrast, there was no change in three other EGFR ligand genes, *Amphiregulin* (*Areg), Transforming growth factor α* (*Tgfα*) and *Egf*. Immunostaining for the active, phosphorylated form of EGFR (p-EGFR), showed expression in in epithelial cells in the control as well as up to three days following myeloid cell depletion, but virtually complete loss of expression by one week ([Figure 2E](#fig2){ref-type="fig"}). Our data support the notion that myeloid cells -- either directly or through interaction with other cell types -- are required for activation of EGFR/MAPK signaling in epithelial cells, thus promoting carcinogenesis while preventing acinar re-differentiation and tissue repair.

In advanced malignancy, myeloid cells promote tumorigenesis by inhibiting CD8^+^ T cell mediated immune responses ([@bib40]; [@bib57]; [@bib63]; [@bib65]), and myeloid cell depletion causes CD8^+^ T cell mediated epithelial cell death. To determine whether a similar immune suppressive mechanism was at play in early lesions, we depleted CD8^+^ T cells along with myeloid cells in mice bearing low-grade lesions ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). CD8^+^ T cell depletion alone had no effect on PanIN progression in iKras\* mice. Conversely, limited acinar cell recovery was induced by myeloid cell depletion (as described above) and similarly observed when both CD8^+^ T cell and myeloid cells were depleted in iKras\*;CD11b-DTR mice ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). Thus, during the early stages of carcinogenesis, suppression of T cell-mediated immune responses does not appear to be the main function of infiltrating m cells.

Oncogenic Kras expression in epithelial cells regulates myeloid cell infiltration and polarization {#s2-2}
--------------------------------------------------------------------------------------------------

To further investigate the cross-talk between oncogenic Kras expressing epithelial cells and infiltrating myeloid cells, we inactivated oncogenic Kras in PanIN bearing iKras\* mice ([Figure 3A](#fig3){ref-type="fig"}, n = 4--7 mice/cohort) ([@bib8]), and harvested pancreata after 3 days, one week or two weeks. We detected abundant macrophages (CD11b^+^CD64^+^F4/80^+^) in pancreata expressing oncogenic Kras as well as 3 days following Kras inactivation, as determined by immunostaining and flow cytometry ([Figure 3B--C](#fig3){ref-type="fig"}). The total number of macrophages was significantly lower 1 week following Kras inactivation. We then used a combination of surface markers to measure different subsets of macrophages. In the presence of oncogenic Kras, most infiltrating macrophages were CD11b^+^CD64^+^F4/80^+^CD11c^+^CD206^-^, consistent with surface characteristics of tumor associated macrophages (TAMs) ([@bib17];[@bib43]; [@bib44]). TAM infiltration decreased following Kras\* inactivation, while CD11b^+^CD64^+^F4/80^+^CD206^+^CD11c^-^ macrophages transiently increased ([Figure 3D](#fig3){ref-type="fig"}). We sorted total myeloid cells (DAPI^-^EGFP^-^CD45^+^CD11b^+^) from iKras\* pancreata prior to or after Kras inactivation. In myeloid cells extracted from oncogenic Kras expressing pancreata, we detected elevated expression of *Arginase 1* (*Arg1*) and *Chitinase 3-like 3 (Chil3) --also known as Ym1--*mediators of the immune response and commonly expressed in TAMs ([@bib18]; [@bib42]; [@bib46]); both markers were downregulated in myeloid cells sorted following Kras inactivation ([Figure 3E](#fig3){ref-type="fig"}). Thus, macrophage polarization is regulated by the Kras status of epithelial cells. To determine whether direct interactions between epithelial cells and myeloid cells mediated expression of *Arg1*, we used an in vitro indirect co-culture system. iKras\* primary cells ([@bib9]) were cultured in presence or absence of DOX to modulate the expression of oncogenic Kras. Conditioned medium from these cells was then used to culture the mouse macrophage cell line RAW264.7. Analysis of the RNA derived from the macrophages by qRT-PCR revealed that cancer cell conditioned media induced *Arg1* expression in macrophages in an oncogenic Kras dependent manner ([Figure 3F](#fig3){ref-type="fig"}).

![Oncogenic Kras in epithelial cells regulates macrophages polarization and function.\
(**A**) Experimental design, n = 4 \~ 8 mice/cohort. (**B**) Immunohistochemistry staining for F4/80 in iKras\* pancreata 3 weeks post pancreatitis and 3 days, 1 week upon Kras\* inactivation. Scale bar 50 µm. (**C**) Pancreatic macrophage (CD11b^+^CD64^+^F4/80^+^) infiltration in iKras\* pancreata 3 week post pancreatitis induction and 3 days, 2 weeks followed by Kras\* inactivation were measured by flow cytometry. (**D**) Percentage of classically activated (CD11b^+^CD64^+^F4/80^+^CD11c^+^CD206^-^) macrophages and alternatively activated (CD11b^+^CD64^+^F4/80^+^CD206^+^CD11c^-^) macrophages in iKras\* pancreata 3 weeks post pancreatitis and 3 days, 2 week upon Kras\* inactivation were analyzed by flow cytometry. Data represent mean ± SEM, each point indicates one animal. The statistical difference was determined by Two-tailed unpaired *t*-tests. p\<0.05. (**E**) qRT-PCR for *Arg1* and *Chil3* expression in myeloid cells flow-sorted from control spleen, iKras\* pancreata 3 weeks post pancreatitis and 3 days post Kras\* inactivation. Data represent mean ± SEM. The statistical difference was determined by Two-tailed unpaired *t*-tests. (**F**) qRT-PCR for *Arg1* expression in macrophages cultured with control IMDM media or iKras\* cancer cell conditioned media (CM) in presence or absence of DOX. Data represent mean ± SEM. The statistical difference was determined by Two-tailed unpaired *t*-tests. (**G**) qRT-PCR for *Egf, Tgfα, Hbegf, Tgfβ1* and *Tnfα* expression in myeloid cells sorted from control spleen, iKras\* pancreata 3 weeks post pancreatitis and 3 days post Kras\* inactivation. Data represent mean ± SEM. The statistical difference was determined by Two-tailed unpaired *t*-tests.](elife-27388-fig3){#fig3}

Further characterization of myeloid cells extracted from oncogenic Kras expressing pancreata revealed high levels of *Hbegf*, *Tgfβ and Tumor necrosis factor-α (Tnfα) (*[Figure 3G](#fig3){ref-type="fig"}). The expression of these ligands was reduced in myeloid cells isolated following Kras inactivation, while other secreted molecules, such as *EGF* and *Tgfα,* did not change ([Figure 3E and G](#fig3){ref-type="fig"}). In parallel with these changes in myeloid cells, we observed a change in the receptor subsets expressed in sorted EGFP^+^ epithelial cells. While *Egfr* expression was high when oncogenic Kras was expressed, and decreased upon its inactivation, *Erbb4* was expressed at a lower level when Kras was active, but increased upon Kras inactivation ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

Thus, oncogenic Kras expression regulates the specific EGFR receptor expressed in the epithelium, as well as regulating polarization and expression of EGFR ligands in infiltrating myeloid cells through a non-cell autonomous mechanism.

Myeloid cells are required for pancreatic acinar cell re-differentiation {#s2-3}
------------------------------------------------------------------------

During the early stages of carcinogenesis, oncogenic Kras, through activation of MAPK signaling, promotes dedifferentiation of acinar cells to ADM ([@bib10]; [@bib22]; [@bib27]; [@bib56]). Conversely, acinar re-differentiation occurs upon inactivation of oncogenic Kras ([@bib8]). While intrinsic factors are known to regulate acinar redifferentiation ([@bib35]; [@bib50]; [@bib51]), the role of the microenvironment is less clear. We investigated the functional role of myeloid cells upon Kras inactivation, during the re-differentiation of acinar cells. We activated oncogenic Kras in adult iKras\* or iKras\*;CD11b-DTR mice and induced acute pancreatitis, to induce widespread PanIN formation. Three weeks later, we inactivated oncogenic Kras by withdrawing DOX and simultaneously treated the mice with DT, and harvested the pancreata 3 days or 1 week later (*see scheme in* [Figure 4A](#fig4){ref-type="fig"}). In DT-treated iKras\* mice, inactivation of oncogenic Kras during the early neoplastic stages leads to re-differentiation of acinar cells and remodeling of the extracellular matrix and fibro-inflammatory stroma ([Figure 4B](#fig4){ref-type="fig"}, *Top Row*). In contrast, depletion of myeloid cells severely impaired this process. A week after Kras inactivation, DT-treated iKras\*;CD11b-DTR pancreata remained fibrotic with very few acinar units identified by histology ([Figure 4B](#fig4){ref-type="fig"}, *Bottom Row,* Trichrome staining in [Figure 4C](#fig4){ref-type="fig"} and pathological quantification in [Figure 4D](#fig4){ref-type="fig"}). Furthermore, PAS staining, indicating mucinous ducts and low-grade PanINs, were still present in a subset of the ductal structures ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). Immunostaining for EGFP, a lineage tracing marker for Cre recombination, showed that the epithelial cells in both iKras\* and iKras\*;CD11b-DTR mice after Kras\* inactivation were derived from PanIN cells that had previously expressed the Kras\* transgene ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}).

![Myeloid cells are required for tissue remodeling upon Kras\* inactivation.\
(**A**) Experimental design (n = 4 \~ 8 mice/cohort). (**B**) H&E staining; (**C**) Gomori Trichrome staining in iKras\* and iKras\*;CD11b-DTR pancreata 3 weeks post pancreatitis induction and 3 days, 1 week following Kras\* inactivation and DT treatment. Scale bar 50μm. (**D**) Pathological analysis for iKras\* and iKras\*;CD11b-DTR pancreata 1 week following Kras\* inactivation and DT treatment. Data represent mean ± SEM, n = 4 mice/cohort. The statistical difference between iKras\* and iKras\*;CD11b-DTR mice per lesion type was determined by Two-tailed unpaired *t*-tests.](elife-27388-fig4){#fig4}

In both iKras\* and iKras\*;CD11b-DTR mice the ductal marker CK19 was prevalent with Kras\* ON. Upon Kras inactivation, iKras\* mice presented with a transient phase of co-expression of CK19 and amylase, prior to re-establishment of normal pancreas architecture ([Figure 5A](#fig5){ref-type="fig"}, *Top Row*). In contrast, in iKras\*;CD11b-DTR mice, ductal structures with co-expression of CK19 and amylase persisted a week after Kras inactivation ([Figure 5A](#fig5){ref-type="fig"}, *Bottom Row*). The newly recovered acinar cells in iKras\* mice were highly proliferative ([Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). In contrast, proliferation was low in iKras\*;CD11b-DTR mice a week after Kras\* inactivation. Conversely, apoptotic cells were rare in iKras\* pancreata, but abundant in the epithelial compartment of iKras\*;CD11b-DTR pancreata as shown by E-cadherin and cleaved caspase three co-immunostaining ([Figure 5B](#fig5){ref-type="fig"}). To determine whether myeloid cell depletion during tissue repair resulted in CD8^+^ T cell mediated immune responses against epithelial cells, we depleted CD8^+^ T cells along with myeloid cells upon Kras\* inactivation ([Figure 5---figure supplement 2A](#fig5s2){ref-type="fig"}). In iKras\* mice, CD8^+^ T cell depletion had no effects on either stroma remodeling or epithelial cell survival, and tissue remodeling occurred as expected. Interestingly, CD8^+^ T cell depletion didn't improve cell survival in iKras\*;CD11b-DTR mice ([Figure 5---figure supplement 2B](#fig5s2){ref-type="fig"}).

![Myeloid cells regulate acinar re-differentiation, cell survival and stromal activation of EGFR/MAPK signaling.\
(**A**) Co-immunofluorescent staining for CK19 (green), Amylase (red), SMA (magenta) and DAPI (blue); (**B**) co-immunofluorescent staining for Cleaved caspase 3 (green), E-cadherin (magenta) and DAPI (blue); (**C**) co-immunofluorescent staining for p-ERK1/2 (green), CK19 (red), SMA (magenta) and DAPI (blue) in iKras\* and iKras\*;CD11b-DTR pancreata 3 weeks post pancreatitis and 3 days, 1 week upon Kras\* inactivation and DT treatment. Scale bar 25 µm. Arrows indicate cells co-expressing p-ERK1/2 and SMA.](elife-27388-fig5){#fig5}

Thus, acinar cell plasticity and survival was regulated by infiltrating myeloid cells, independently from their ability to regulate anti-tumor immune responses.

Pancreatic remodeling requires stromal activation of EGFR/MAPK signaling {#s2-4}
------------------------------------------------------------------------

Inactivation of oncogenic Kras in pre-neoplastic iKras\* pancreata results in a reduction of epithelial p-ERK expression ([@bib8]). Surprisingly, p-ERK downregulation in the epithelium coincided with a transient activation of p-ERK in the stroma ([Figure 5C](#fig5){ref-type="fig"}). To positively identify the stromal components expressing p-ERK, we performed a panel of co-immunostaining. SMA, a marker of activated fibroblasts, was rapidly reduced upon oncogenic Kras inactivation ([@bib8]); yet we observed expression of p-ERK in a subset of SMA^+^ cells ([Figure 5C](#fig5){ref-type="fig"}, yellow arrows). We observed extensive co-localization of p-ERK with the fibroblast markers Vimentin and Platelet-derived growth factor receptor β (PDGFRβ) ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). In contrast, F4/80^+^ macrophages only rarely expressed measurable but low levels of p-ERK ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}). Interestingly, myeloid cell ablation prevented p-ERK up-regulation in the stroma upon Kras inactivation ([Figure 5C](#fig5){ref-type="fig"}). These data are consistent with the hypothesis that myeloid cells provide essential factors that activate EGFR/MAPK signaling in stromal fibroblasts.

We then examined the expression of EGFR ligands and downstream matrix metalloproteinases (MMPs) in our models using qRT-PCR. *Egf* and *Tgfα* levels were significantly up-regulated in iKras\* pancreata 3 days following Kras\* inactivation, whereas the levels of other EGFR ligands *Hbegf, Areg* and *Ereg* were high in neoplastic pancreata (Kras\* ON) and dramatically down-regulated when Kras\* was inactivated. Depletion of myeloid cells prevented the increase in *Egf* and *Tgfα* upon Kras inactivation ([Figure 6A](#fig6){ref-type="fig"}). Among the MMPs we examined*, Mmp1* was upregulated in iKras\* pancreata 3 days following Kras\* inactivation. We observed a similar trend for *Mmp2* and *Mmp9* while the expression of *Mmp12* and *Mmp14* did not change. However, their expression was slightly (but not significantly) decreased upon myeloid cell depletion ([Figure 6A](#fig6){ref-type="fig"}). To identify the source of EGFR ligands and MMPs during Kras inactivation induced tissue repair, we flow sorted myeloid cells (DAPI^-^EGFP^-^CD45^+^CD11b^+^), fibroblasts (DAPI^-^EGFP^-^CD45^-^CD3^-^CD11b^-^CD31^-^) and epithelial cells (EGFP^+^CD45^-^) for RNA extraction. qRT-PCR analysis showed that *Egf* and *Tgfα* were present in both myeloid cells and fibroblasts, at similar levels independently from the oncogenic Kras status ([Figure 3G](#fig3){ref-type="fig"} and [Figure 6B](#fig6){ref-type="fig"}). *Hbegf*, as mentioned earlier, was expressed in a Kras-dependent manner in myeloid cells ([Figure 3G](#fig3){ref-type="fig"}), but not expressed in fibroblasts (*data not shown*). *EGFR* was expressed in fibroblasts independently of epithelial Kras status ([Figure 6B](#fig6){ref-type="fig"}). The EGFR/MAPK pathway regulates expression of ECM degrading enzymes in various types of cells including fibroblasts ([@bib29]). Accordingly, MMPs expression was detected in both myeloid cells and fibroblasts. In particular, *Mmp2* expression in fibroblasts derived from iKras\* was up-regulated when Kras\* was OFF for 3 days and significantly higher compared to that in fibroblasts derived from iKras\*;CD11b-DTR. Further, *Mmp9* expression in fibroblasts decreased upon myeloid cell depletion ([Figure 6B](#fig6){ref-type="fig"}). Western-blot analysis of the pancreata showed a reduction in overall *Mmp2* protein levels, and specifically the active form of the protein, upon myeloid cell depletion ([Figure 6C](#fig6){ref-type="fig"}). Interestingly, Western-blot analysis also revealed a decrease in Collagen I levels following Kras\* inactivation in iKras\* mice but not in iKras\*;CD11b-DTR mice, indicating impaired remodeling in the latter ([Figure 6C](#fig6){ref-type="fig"}). In addition to myeloid cells, epithelial cells might constitute a source of EGFR ligands. By q-PCR analysis, we detected expression of *Egf*, *Tgfα* and *Hbegf* mRNA in sorted epithelial cells; the expression of *Egf* was decreased upon myeloid cell depletion while expression of the other ligands was unchanged ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}).

![Oncogenic Kras regulates EGFR ligands and MMPs production.\
(**A**) qRT-PCR for *Egf, Tgfα, Hbegf, Areg, Ereg, Mmp1, Mmp2, Mmp9, Mmp12* and *Mmp14* expression in littermate control, iKras\* pancreata 3 weeks post pancreatitis, iKras\* and iKras\*;CD11b-DTR pancreata 3 days post Kras\* inactivation and DT treatment. Data represent mean ± SEM, each point indicates one animal. The statistical difference was determined by Two-tailed unpaired *t*-tests. (**B**) qRT-PCR for *Egfr, Egf, Tgfα, Mmp2* and *Mmp9* expression in fibroblasts freshly sorted from control normal pancreata, iKras\* pancreata 3 weeks post pancreatitis, iKras\* and iKras\*;CD11b-DTR pancreata 3 days post Kras\* inactivation and DT treatment. Data represent mean ±SEM. n.d.: no detection. The statistical difference was determined by Two-tailed unpaired *t*-tests. (**C**) Western-blot analysis for Collagen type I, MMP2 and β-actin in iKras\* pancreata 3 weeks post pancreatitis, 3 days, 1 week upon Kras\* inactivation and in iKras\*;CD11b-DTR pancreata 1 week upon Kras\* inactivation and DT treatment.](elife-27388-fig6){#fig6}

Based on our data, myeloid cells might contribute to EGFR ligand levels both by expressing them directly, and by inducing their expression in other cells types (epithelial, and possibly others).

To determine whether EGFR/MEK activation in fibroblasts was required for tissue remodeling, we inhibited EGFR or MEK -- a key component of MAPK signaling- with Erlotinib and Tramatinib, respectively. First, we let iKras\* mice develop low-grade PanINs, as described above. Then, upon inactivation of oncogenic Kras, we treated the animals with the inhibitors or vehicle controls ([Figures 7A](#fig7){ref-type="fig"} and [8A](#fig8){ref-type="fig"}). EGFR inhibition (EGFRi) blocked MAPK activation in the stroma as measured by reduced p-ERK levels ([Figure 7B](#fig7){ref-type="fig"}). Similar to myeloid cell depletion, EGFRi treatment resulted in delayed tissue repair. Abundant stroma was still present at 1 week post Kras\* inactivation ([Figure 7B](#fig7){ref-type="fig"}, HE and Trichrome staining). Further, *Mmp2* and *Mmp9* expression was inhibited in EGFRi treated pancreata 3--7 days post Kras\* inactivation ([Figure 7C](#fig7){ref-type="fig"}). However, acinar re-differentiation was not affected by EGFRi treatment, as shown by co-immunofluorescent staining for CK19 and amylase ([Figure 7B](#fig7){ref-type="fig"}).

![EGFR inhibition impairs ECM remodeling and tissue repair upon Kras\* inactivation.\
(**A**) Experimental design, n = 4 \~ 6 mice/cohort. (**B**) H&E staining, Gomori Trichrome staining (inset), co-immunofluorescent staining for p-ERK1/2 (green), CK19 (red), SMA (magenta) and DAPI (blue), co-immunofluorescent staining for CK19 (green), Amylase (red), SMA (magenta) and DAPI (blue) and immunohistochemistry staining for p-EGFR in iKras\* pancreata 3 weeks post pancreatitis induction followed by Kras\* inactivation and EGFR inhibitor (EGFRi) treatment for 3 days and 1 week. Scale bar 25 µm. (**C**) qRT-PCR for *Mmp2* and *Mmp9* expression in littermate control pancreata, iKras\* 3 weeks post pancreatitis, iKras\* 3--7 days followed by Kras\* inactivation and treated with either vehicle or EGFRi. Data represent mean ± SEM, each point indicates one animal. The statistical difference was determined by Two-tailed unpaired *t*-tests.](elife-27388-fig7){#fig7}

![Stroma remodeling upon Kras\* inactivation depends on MEK/ERK activity in stroma.\
(**A**) Experimental design, n = 4 \~ 5 mice/cohort. (**B**) H&E staining, Gomori Trichrome staining (inset), co-immunofluorescent staining for p-ERK1/2 (green), CK19 (red), SMA (magenta) and DAPI (blue) and co-immunofluorescent staining for CK19 (green), Amylase (red), SMA (magenta) and DAPI (blue) in iKras\* pancreata 3 weeks post pancreatitis induction followed by Kras\* inactivation and MEK inhibitor (MEKi) treatment for 3 days and 1 week. Scale bar 25 µm. (**C**) qRT-PCR for *Mmp2* and *Mmp9* expression in littermate control pancreata, iKras\* 3 weeks post pancreatitis, iKras\* 3--7 days followed by Kras\* inactivation and treated with either vehicle or MEKi. Data represent mean ± SEM, each point indicates one animal.](elife-27388-fig8){#fig8}

We made similar observations upon MEK inhibition (MEKi) upon Kras\* inactivation, with reduced ECM degradation and MMPs expression ([Figure 8B and C](#fig8){ref-type="fig"}), but unimpaired acinar re-differentiation. Therefore, EGFR-MAPK signaling is required for ECM degradation and remodeling. Conversely, in the epithelium, repression of EGFR/MAPK promoted re-differentiation, consistent with previous studies ([@bib2]; [@bib10]).

Discussion {#s3}
==========

The pancreas is formed by a limited number of progenitor cells and, in the adult, it has a limited ability to regenerate following injury ([@bib15]), although it can grow in response to increase need for its exocrine or endocrine function ([@bib26]; [@bib31]). The pancreas is highly plastic; in particular, acinar cells can de-differentiate into duct-like cells during a process known as acinar-ductal metaplasia (ADM). While ADM is important during tissue damage such as acute pancreatitis -where it might protect acinar cells from further damage and set the stage for repair- it also leads to a cell type that is susceptible to transformation by oncogenic Kras (for review see \[[@bib41]; [@bib49]\]). Thus, the mechanisms regulating pancreas plasticity are relevant to both damage/repair in this organ and carcinogenesis.

ADM is characterized by loss of acinar differentiation and acquisition of a duct-like phenotype which is accompanied by expression of pancreas progenitor markers ([@bib45]; [@bib49]; [@bib54]; [@bib55]). Transcription factors driving acinar differentiation are down-regulated during ADM. BHLHA15 expression is lost during ADM and re-established when ADM re-differentiates to acini. Importantly, BHLHA15 plays a functional role in this process, and while BHLHA15 loss facilitates ADM (and, consequently, carcinogenesis), forced expression of BHLHA15 is protective against both ADM and carcinogenesis ([@bib51]). The transcription factor Ptf1a is expressed throughout the pancreatic bud early in development, but it is restricted to acinar cells in the adult organ ([@bib32]). Ptf1a loss facilitates ADM and carcinogenesis ([@bib35]). Further, PDX1, a key determinant of pancreas development expressed at low levels in adult acini, is similarly important to maintain acinar cell identity ([@bib50]). Thus, signals intrinsic to epithelial cells regulate the differentiation status of acinar cells. We have, and others, have previously shown that oncogenic Kras induces ADM through activation of MAPK signaling ([@bib2]; [@bib10]; [@bib11]) and consequent repression of acinar-specific transcription factors. Conversely, inhibition of MAPK signaling using MEK inhibitors allows re-expression of acinar-specific transcription factors and re-differentiation of acinar cells ([@bib10]). Thus, a complex network of intrinsic signals regulates acinar differentiation in the adult pancreas.

In our initial characterization of the iKras\* mouse model, we investigated the role of oncogenic Kras during very early stages of carcinogenesis. While oncogenic Kras promotes transdifferentiation of acinar cells to acinar-ductal metaplasia, inactivation of oncogenic Kras in ADM or even low-grade PanIN lesions leads to regression of these lesions and re-differentiation of the epithelial compartment to acinar cells ([@bib8]). Inactivation of oncogenic Kras also results in profound remodeling of the surrounding fibroinflammatory reaction. Here, we set out to understand the interaction between oncogenic Kras expressing epithelial cells and the surrounding microenvironment. We show that reciprocal interactions between oncogenic Kras expressing epithelial cells and the surrounding microenvironment control pancreatic plasticity (see working model in [Figure 9](#fig9){ref-type="fig"}). *First,* we determined that Kras expressing epithelial cells alter myeloid cell polarization in the pancreas, inducing expression of *Arginase1, Chil3* and *Hbegf*. These markers have been previously described in tumor associated macrophages (TAMs, for review see \[[@bib38]\]). *Second,* Inactivation of oncogenic Kras led to the loss of *Arg1*, *Chil3* and *Hbegf from myeloid cells.* Conversely, a subset of macrophages positive for the surface markers CD206 and CD11c, transiently accumulated in the pancreas, coinciding with the remodeling process. Interestingly, the surface marker expression of this population is consistent with M2 macrophages previously shown to be important in regeneration of pancreatic acini and islets following experimental ablation ([@bib12]), and similarly involved in tissue repair in other organs (for review, see \[[@bib59]\]).

![Diagram depicting our working model.\
(**A**) In the presence of epithelial oncogenic Kras expression, myeloid cells are required to maintain high MAPK activity in the epithelial cells themselves, and thus maintain de-differentiation and promote PanIN formation. At the same time, myeloid cells are required for the activation status of stromal fibroblasts. These effects are, at least in part, mediated by secretion of EGFR ligands. Myeloid cells are a source of HB-EGF (maroon drops), which is possibly also secreted by epithelial cells. Further, other EGFR ligands (purple drops) are secreted by cells within the microenvironment. (**B**) Myeloid cell depletion leads to re-differentiation of PanIN cells and loss of fibroblast activation, notwithstanding continuous expression of oncogenic Kras. (**C**) Oncogenic Kras inactivation in epithelium redirects myeloid cell polarization and function; thus inducing MAPK activation in fibroblasts to promote extracellular matrix remodeling. (**D**) Myeloid cell depletion following Kras\* inactivation results in impaired pancreatic tissue repair.](elife-27388-fig9){#fig9}

In this study, we show that myeloid cells play an instructive role regulating epithelial cell identity and plasticity. In the presence of oncogenic Kras, myeloid cells are required to maintain dedifferentiation of ADM/low-grade PanIN lesions. Depletion of myeloid cells induces BHLHA15 expression and occasionally expression of the digestive enzyme amylase in low-grade PanINs, notwithstanding expression of oncogenic Kras, thus presumably preventing further progression to malignancy. We show that myeloid cells are required for the expression of EGF ligands, and activation of MAPK signaling in pancreatic epithelial cells. This finding fits with the notion that oncogenic Kras is insufficient to induce a high enough level of MAPK activation to induce transformation ([@bib13]), thus EGFR ligands are required for carcinogenesis ([@bib2]).

In tumor-bearing mice, myeloid cells inhibit CD8^+^ T cell mediated anti-tumor immune responses, and this function explains their requirement in cancer growth ([@bib57]; [@bib63]). However, both during the progression of early PanIN lesions and during their regression upon Kras inactivation, myeloid cell-requirement was independent from the presence of CD8^+^ T cells, indicating that they play a function distinct from immune suppression. Upon Kras inactivation, myeloid cells including re-polarized M2 macrophages are required for tissue remodeling. *First*, we show that myeloid cells are required for epithelial cell re-differentiation and survival. Thus, myeloid cell depletion results in epithelial cell death and persistence of clusters of cells co-expressing acinar and ductal markers. *Second,* we show that myeloid cells are required for remodeling of the extracellular matrix. To gain mechanistic insight, we investigated the cross-talk between epithelial cells and myeloid cells. We have previously shown that myeloid cells are required to sustain activation of EGFR/MAPK signaling in epithelial cells ([@bib63]). In turn, MAPK signaling is necessary for PanIN formation and progression ([@bib2]; [@bib10]; [@bib11]). Surprisingly, remodeling of the extracellular matrix was also regulated by EGFR/MAPK signaling. Inactivation of oncogenic Kras in the pancreas led to changes of expression of specific EGFR ligands in the pancreas. In presence of active Kras, *Hbegf*, *Areg* and *Ereg* were the main ligands. Upon Kras\* inactivation, their expression decreased while that of *Egf* and *Tgfα* increased. In parallel, we observed changes in expression of EGFR family receptors. Remarkably, inactivation of oncogenic Kras resulted in transient activation of MAPK signaling in stromal fibroblasts, simultaneous to loss of activation in the epithelium. Consistent with the notion that MAPK signaling in the stroma is important for remodeling, treatment with Erlotinib (EGFR inhibitor) or Tramatinib (MEK inhibitor) resulted in the persistence of pancreatic fibrosis. The observation that activation of EGFR/MAPK signaling in different cellular compartments might, in turn, favor carcinogenesis or remodeling has potential clinical implications, suggesting that specific inhibition of distinct EGFR ligands or receptors might be preferable to overall inhibition. While our data support the notion that myeloid cells are a source of EGFR ligands, they also support the idea that myeloid cells induce EGFR ligands in other cellular compartments, including epithelial cells; future studies will need to address the role of specific EGFR ligands and their specific cell sources.

In summary, in this study we show that the cross-talk between epithelial cells and myeloid cells regulates pancreatic plasticity and fibrosis. Further, we show that this cross-talk is important for pancreatic tissue repair following injury, but can be co-opted, in presence of oncogenic Kras, to promote carcinogenesis. Manipulating this cross-talk to promote repair while inhibiting carcinogenesis should therefore be prioritized in future studies.

Materials and methods {#s4}
=====================

Mice  {#s4-1}
-----

iKras\*;CD11b-DTR mice were generated by crossing iKras\* mice (ptf1a-Cre;R26-rtTa-IRES-EGFP;TetO-Kras^G12D^) ([@bib8]) with CD11b-DTR mice (B6.FVB-Tg(ITGAM-DTR/EGFP)34Lan/J*, Jackson* Laboratory) ([@bib16]). Double mutant littermates of iKras\* were used as controls. Male and female mice were included equally. All animal studies were conducted in compliance with the guidelines of Institutional Committees on Use and Care of Animals at the University of Michigan.

Animal experiments {#s4-2}
------------------

Acute pancreatitis was induced in 4--6 week-old mice by caerulein injection and Kras^G12D^ expression was induced by doxycycline as previously described ([@bib8]). Three weeks post pancreatitis induction doxycycline was withdrawn from the drinking water for tissue repair study. Mice were also treated with EGFR inhibitor Erlotinib (50 mg/kg, oral gavage, daily) (Selleckchem), or MEK inhibitor Tramatinib (GSK1120212) (1 mg /kg, i.p. daily) (Selleckchem) or vehicle. For myeloid cell depletion, CD11b-DTR and iKras\*;CD11b-DTR mice were treated with diphtheria toxin (DT) (25 ng/g i.p.) (Enzo Life Science) and repeated every 4 days. For CD8^+^ T cell depletion, anti-CD8 mAb (BioXcell \#BE0061; clone 2.43; 200 µg/mouse) was injected i.p. twice per week.

Cell culture {#s4-3}
------------

All cells were cultured in IMDM supplemented with 10% FBS and 1% penicillin/streptomycin (Gibco). Primary mouse pancreatic cancer cell line iKras\* derived from iKras\*p53\* (ptf1a-Cre; TetO-Kras^G12D^; Rosa26^rtTa/+^; p53^R172H/+)^ tumor ([@bib9]) was used to generate conditioned medium (CM) in presence or absence of Doxycycline at 1 µg/ml (Sigma) for 2--3 days. These cells were used at low passage, genotyped for the Kras, Cre and p53 transgenes, and tested negative for mycoplasma. Mouse macrophage cell line RAW264.7 (ATCC Cat\# TIB-71, RRID:[CVCL_0493](https://scicrunch.org/resolver/CVCL_0493)) were similarly used at low passage and mycoplasma negative. CM was filtered through 0.2 µm filter before use. 1--2 × 10^5^ cells of RAW264.7 were plated in 6-well plates overnight and then cultured with CM (iKras\* CM diluted 1:1 in fresh IMDM with 10% FBS) for 24 hr before harvest for RNA isolation.

Histopathological analysis {#s4-4}
--------------------------

Hematoxylin and eosin (H&E), Periodic Acid Schiff (PAS), Gomori's Trichrome, immunohistochemical and immunofluorescent staining were performed on formalin-fixed, paraffin embedded mouse pancreatic tissues as described before ([@bib62]). Antibodies used are listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. For immunofluorescence, Alexa Fluor (Invitrogen) secondary antibodies were used. Cell nuclei were counterstained with Prolong Gold with DAPI (Invitrogen). Images were taken with Olympus BX-51 microscope, Olympus DP71 digital camera, and DP Controller software. The immunofluorescent images were acquired using the Olympus IX-71 confocal microscope and FluoView FV500/IX software. For histopathological analysis, five non-overlapping H&E images (20x objective) per slide were examined by a pathologist (W.Y.) as described before ([@bib62]). Image-Pro Plus 4.5 was used to measure the percentage of positive area of immunofluorescent staining per high power field image. Three samples per group, and 4--6 images per sample were analyzed.

Western blotting {#s4-5}
----------------

Western blotting was conducted as previously described ([@bib8]), and Collagen I was detected under non-reduced and non-denatured condition. Antibody information is included in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

Flow cytometric analysis and sorting {#s4-6}
------------------------------------

Single-cell suspensions of fresh spleen or pancreas were prepared as previously described ([@bib64]) and stained with fluorescently conjugated antibodies listed in [Supplementary file 1](#supp1){ref-type="supplementary-material"}. Flow cytometric analysis was performed on a Cyan ADP analyzer (Beckman Coulter) and data were analyzed with Summit 4.3 software. Cell sorting was performed using a MoFlo Astrio (Beckman Coulter). Myeloid cells (DAPI^-^EGFP^-^CD45^+^CD11b^+^), epithelial cells (DAPI^-^EGFP^+^CD45^-^) and fibroblasts (DAPI^-^EGFP^-^CD45^-^CD11b^-^CD31^-^CD3^-^) were sorted and lysed in RLT buffer (Qiagen). Total RNA was prepared using RNeasy (Qiagen) and reverse-transcripted using High Capacity cDNA Reverse Transcription kit (Applied Biosystems).

Quantitative RT-PCR {#s4-7}
-------------------

Samples for quantitative PCR were prepared with 1X SYBR Green PCR Master Mix (Applied Biosystems) and various primers (primer sequences are listed in [Supplementary file 2](#supp2){ref-type="supplementary-material"}). All primers were optimized for amplification under reaction conditions as follows: 95^°^C 10mins, followed by 40 cycles of 95^°^C 15 secs and 60^°^C 1 min. Melt curve analysis was performed for all samples after the completion of the amplification protocol. Cyclophilin A was used as the housekeeping gene expression control.

Statistical analysis {#s4-8}
--------------------

Graphpad Prism six software was used for all statistical analysis. All data were presented as means ± standard error (SEM). Intergroup comparisons were performed using Two-tailed unpaired *t*-test, and p\<0.05 was considered statistically significant.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Epithelial-Myeloid cell crosstalk regulates acinar cell plasticity and pancreatic remodeling in mice\" for consideration by *eLife*. Your article has been favorably evaluated by Didier Stainier (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This is a very interesting and well-executed study demonstrating highly context dependent contrasting roles for myeloid cells, likely macrophages, in initiation and regression of pancreatic cancer development and tissue remodeling. Using their elegant model of pancreatic ductal adenocarcinoma (PDA) with inducible KRASG12D expression coupled with depletion of CD11b+ myeloid cells, the authors interrogate effects on early disease development and tissue remodeling to show that myeloid cells are critical not only to disease development but also for tissue remodeling following silencing of oncogenic Kras. The three key findings are: ([@bib1]) established PanINs, induced by oncogenic Kras, require macrophages for their maintenance, and undergo at least partial re-differentiation when macrophages are ablated; ([@bib2]) the regression of PanINs that occurs when oncogenic Kras is turned off *also* requires macrophages; and ([@bib3]) these contrasting roles reflect EGFR/MAPK signaling, dependent on macrophages, being activated in epithelial vs. stromal (fibroblast) cells.

Essential revisions:

While most of the data are well presented and provide important and novel insights, it would be very useful if the authors were to address concerns that many of the links that they make are descriptive correlations rather than causally established. Some concerns, as identified below, require new data, while other concerns require substantial textual modifications.

Concerns requiring new data:

1\) While the manuscript shows that CD8 T cells do not mediate cell killing in the Kras\*-off/DT model, it is critical to establish this in the Kras\*-on/DT model. It is important to determine if the major role of macrophages at this early stage is to suppress anti-tumor immunity (which the authors\' own prior studies have established as quite potent under certain circumstances, even in early PanINs). This is important because the data here are consistent not only with the authors\' preferred model of PanINs depending on macrophage-delivered EGFR ligands, but also with a model in which PanIN persistence requires ongoing immune suppression by the macrophages. (See also point 3, below, regarding an alternative model for the pro-remodeling role of macrophages.)

2\) In [Figure 2D](#fig2){ref-type="fig"}, while it is interesting that the authors observe increased levels of the EGFR ligand Hb-egf, there are several ligands that can activate EGFR. To interrogate the interactions more thoroughly, the authors should examine the expression of other ligands. Moreover, as the authors have examined levels of other EGFR ligands in subsequent experiments ([Figure 6](#fig6){ref-type="fig"}), addressing the levels of other ligands related to [Figure 2D](#fig2){ref-type="fig"} will provide a basis for better comparing the differential role of macrophages in disease development and resolution.

Concerns requiring extensive textual modifications:

3\) If one compares the expression of EGFR ligands between whole pancreas ([Figure 6A](#fig6){ref-type="fig"}), sorted myeloid cells ([Figure 3G](#fig3){ref-type="fig"}) and sorted fibroblasts ([Figure 6B](#fig6){ref-type="fig"}), an alternative model can be suggested: both EGF and TGFalpha are elevated in whole pancreas specifically upon Kras\* inactivation, in a macrophage-dependent manner, suggesting that *epithelial cells* are a potential source of ligands acting on fibroblasts during repair, and that the role of macrophages is to induce epithelial cells to produce these ligands. This is also consistent with the pEGFR staining in [Figure 7B](#fig7){ref-type="fig"}, where positive fibroblasts are seen adjacent to positive epithelial cells, suggesting autocrine/paracrine signaling from the epithelium. This is at least a likely model, especially since there are no data provided showing that macrophages activate induce pEGFR in co-cultured pancreatic fibroblasts. The authors should acknowledge and address such alternative models and/or provide additional data to justify their model of a macrophage source for EGFR ligands.

4\) Experiments described in this manuscript have only involved depletion of myeloid cells, not specifically macrophages. Statements such as \"we show that M2 macrophages are required for epithelial cell re-differentiation and survival\" are thus not well supported. Clear distinctions between myeloid cells and macrophages should be made throughout the text. In fact, although it has presumably been defined in other studies, it would be useful for the authors to clearly indicate just what types of myeloid cells are being depleted in DT-injected CD11b-DTR mice. Presumably, dendritic cells or granulocytes are not being depleted, but the term \"myeloid cells\" is very broad and it is advisable to have some more specific description.

5\) The discussion of macrophage subtypes is confusing and contradictory (e.g. subsection "Oncogenic Kras expression in epithelial cells regulates myeloid cell infiltration and polarization" and Discussion, third paragraph). On the one hand, cell surface markers are interpreted as showing a transient increase in \"alternatively activated macrophages\" after Kras\* inactivation. But in the same paragraph, the authors state that Arg1 and Ym1 mRNA expression, \"commonly expressed in alternatively activated macrophages,\" is high in macrophages of Kras\* expressing mice, and these markers clearly decline after Kras\* inactivation ([Figure 3E](#fig3){ref-type="fig"}). The data are the data, and probably indicate that our definitions of macrophage subtypes are imprecise, but the authors need to provide some interpretation of these inconsistencies rather than over-use the term \"alternatively activated.\"

6\) Related to [Figure 1E](#fig1){ref-type="fig"}, the authors write \"myeloid cell depletion resulted in a striking reduction in MAPK...\". This is an observation showing correlation and not causality and should be presented as such.

7\) The authors write, \"These data suggest that myeloid cells provide essential signals to activate EGFR/MAPK signaling in epithelial cells...\" The observations provide correlation and not causality, which should be reflected in the statement -- there are no data presented to suggest this is necessarily a specific effect of myeloid secreted HB-Egf on the epithelial cells.

10.7554/eLife.27388.024

Author response

> Essential revisions:
>
> While most of the data are well presented and provide important and novel insights, it would be very useful if the authors were to address concerns that many of the links that they make are descriptive correlations rather than causally established. Some concerns, as identified below, require new data, while other concerns require substantial textual modifications.
>
> Concerns requiring new data:
>
> 1\) While the manuscript shows that CD8 T cells do not mediate cell killing in the Kras\*-off/DT model, it is critical to establish this in the Kras\*-on/DT model. It is important to determine if the major role of macrophages at this early stage is to suppress anti-tumor immunity (which the authors\' own prior studies have established as quite potent under certain circumstances, even in early PanINs). This is important because the data here are consistent not only with the authors\' preferred model of PanINs depending on macrophage-delivered EGFR ligands, but also with a model in which PanIN persistence requires ongoing immune suppression by the macrophages. (See also point 3, below, regarding an alternative model for the pro-remodeling role of macrophages.)

This is an important point, and we agree with the reviewers that it is an essential complement to our initial data. We have now addressed this question experimentally, and believe that the new data strengthens the manuscript.

In brief, iKras\* and iKras\*;CD11b-DTR mice were placed on DOX to activate oncogenic Kras expression. We then induced acute pancreatitis to promote ADM and PanIN formation. After 3 weeks, when the mice have widespread lesions though the pancreas, we randomized mice of each genotype to either anti-CD8 or isotype control (IgG) and Diphtheria Toxin. In iKras\* mice (where the DT treatment has no effect on myeloid cells), CD8^+^ T cell depletion did not change lesion progression, consistent with the notion that limited/no immune suppression of pancreatic cancer occurs in immune competent mice. In iKras\*;CD11b-DTR mice, DT treatment resulted in depletion of myeloid cells and 1 week after depletion we observed regression of PanINs and partial repopulation of acini. CD8^+^ T cell depletion did not impair nor promote PanIN regression. Thus, the requirement for myeloid cells during the early stages of both carcinogenesis and repair does not depend on their ability to block anti-tumor T cell responses. The new data is included in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"},and addressed in the last paragraph of the subsection "Myeloid cells are required for PanIN maintenance and progression".

> 2\) In [Figure 2D](#fig2){ref-type="fig"}, while it is interesting that the authors observe increased levels of the EGFR ligand Hb-egf, there are several ligands that can activate EGFR. To interrogate the interactions more thoroughly, the authors should examine the expression of other ligands. Moreover, as the authors have examined levels of other EGFR ligands in subsequent experiments ([Figure 6](#fig6){ref-type="fig"}), addressing the levels of other ligands related to [Figure 2D](#fig2){ref-type="fig"} will provide a basis for better comparing the differential role of macrophages in disease development and resolution.

The reviewers are correct, that a more comprehensive analysis of EGFR ligands should have been included. We have now performed and included qPCR analysis for *Ereg, Areg, Tgfα*, and *Egf*. Interestingly, myeloid cell depletion in low-grade PanINs results in a reduction of *Ereg --* similar to what we previously observed for *Hb-egf-* but no change in *Tgfα*, and *Egf.* There was also no significant change in *Areg* although we observed a slight trend towards decrease.The new data is included in [Figure 2D](#fig2){ref-type="fig"}, and described in the second paragraph of the subsection "Myeloid cells are required for PanIN maintenance and progression".

> Concerns requiring extensive textual modifications:
>
> 3\) If one compares the expression of EGFR ligands between whole pancreas ([Figure 6A](#fig6){ref-type="fig"}), sorted myeloid cells ([Figure 3G](#fig3){ref-type="fig"}) and sorted fibroblasts ([Figure 6B](#fig6){ref-type="fig"}), an alternative model can be suggested: both EGF and TGFalpha are elevated in whole pancreas specifically upon Kras\* inactivation, in a macrophage-dependent manner, suggesting that epithelial cells are a potential source of ligands acting on fibroblasts during repair, and that the role of macrophages is to induce epithelial cells to produce these ligands. This is also consistent with the pEGFR staining in [Figure 7B](#fig7){ref-type="fig"}, where positive fibroblasts are seen adjacent to positive epithelial cells, suggesting autocrine/paracrine signaling from the epithelium. This is at least a likely model, especially since there are no data provided showing that macrophages activate induce pEGFR in co-cultured pancreatic fibroblasts. The authors should acknowledge and address such alternative models and/or provide additional data to justify their model of a macrophage source for EGFR ligands.

We have addressed this comment both by performing additional experiments and by modifying the text. We have analyzed sorted epithelial cells for the expression on EGFR ligands, and detected expression of *Egf, Tgfα* and *HB-Egf*; further, at least for a subset of these ligands, epithelial expression decreased upon myeloid cell depletion. The new data is included in [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}.

Thus, it is likely that the effect of myeloid cells on EGFR signaling is two-fold: 1) direct secretion of ligands and 2) promotion of ligand expression from other cell types, including epithelial cells. We have modified accordingly the subsection "Pancreatic remodeling requires stromal activation of EGFR/MAPK signaling", the model in [Figure 9](#fig9){ref-type="fig"}, and the description of the model in the Discussion section.

> 4\) Experiments described in this manuscript have only involved depletion of myeloid cells, not specifically macrophages. Statements such as \"we show that M2 macrophages are required for epithelial cell re-differentiation and survival\" are thus not well supported. Clear distinctions between myeloid cells and macrophages should be made throughout the text. In fact, although it has presumably been defined in other studies, it would be useful for the authors to clearly indicate just what types of myeloid cells are being depleted in DT-injected CD11b-DTR mice. Presumably, dendritic cells or granulocytes are not being depleted, but the term \"myeloid cells\" is very broad and it is advisable to have some more specific description.

We thank the reviewers for pointing out a potential confusing description of our results. We have checked through the text and amended "macrophage" to myeloid cells wherever appropriate. We use the term "macrophage" only where it can be fully justified, namely when we use macrophage-specific markers such as F4/80. Further, although, as the reviewers suggest, previous characterization of the CD11b-DTR model was performed in the initial description, we have performed experiments to determine the profile of myeloid depletion in our hands. For this purpose, we have used a single-dose DT treatment in control or CD11b-DTR mice following induction of acute pancreatitis. The single dose DT is less efficient than the multiple doses we use in the rest of the manuscript, but here our goal was not to achieve maximum depletion, but to determine whether different cellular subsets are depleted with different efficacy. As shown in [Figure 1---figure supplement 1A-B](#fig1s1){ref-type="fig"},macrophages and myeloid derived suppressor cells were depleted at about the same rate as total myeloid cells. In contrast, dendritic cells were *not/only slightly* affected. These results are described in the first paragraph of the subsection "Myeloid cells are required for PanIN maintenance and progression".

> 5\) The discussion of macrophage subtypes is confusing and contradictory (e.g. subsection "Oncogenic Kras expression in epithelial cells regulates myeloid cell infiltration and polarization" and Discussion, third paragraph). On the one hand, cell surface markers are interpreted as showing a transient increase in \"alternatively activated macrophages\" after Kras\* inactivation. But in the same paragraph, the authors state that Arg1 and Ym1 mRNA expression, \"commonly expressed in alternatively activated macrophages,\" is high in macrophages of Kras\* expressing mice, and these markers clearly decline after Kras\* inactivation ([Figure 3E](#fig3){ref-type="fig"}). The data are the data, and probably indicate that our definitions of macrophage subtypes are imprecise, but the authors need to provide some interpretation of these inconsistencies rather than over-use the term \"alternatively activated.\"

The reviewers rightly point out that our nomenclature was confusing. In part, this reflects the difficulty to define distinct subtypes of macrophages, as these cells are plastic and exist in a continuum of different forms. To add to the difficulty, multiple subsets of myeloid derived suppressor cells are also present within the tissue. We now have changed the text in the following way:

a\) In the Results section, we describe both surface markers and expression of specific functional markers (such as Arg1). We further indicate that expression of Arg1 is common in tumor associated macrophages (TAMs).

b\) In the Discussion, we compare the myeloid cells and macrophages subsets to similar subtypes in the literature. We also made sure to distinguish between myeloid cells and macrophages based on the specific experiment.

Accordingly, we amended the text extensively in the subsection "Oncogenic Kras expression in epithelial cells regulates myeloid cell infiltration and polarization" [and in the Discussion section]{.ul}. While we trust these changes improve the clarity of our description, we have to acknowledge that defining macrophage subsets is complicated, and we --as well as other groups- are actively working at trying to define their nature, their recruitment and changes over time.

> 6\) Related to [Figure 1E](#fig1){ref-type="fig"}, the authors write \"myeloid cell depletion resulted in a striking reduction in MAPK...\". This is an observation showing correlation and not causality and should be presented as such.

The reviewers are correct, and we have modified the text to avoid suggesting causality. The text now reads: "... upon myeloid cell depletion, we observed a reduction in MAPK activation...".

> 7\) The authors write, \"These data suggest that myeloid cells provide essential signals to activate EGFR/MAPK signaling in epithelial cells...\" The observations provide correlation and not causality, which should be reflected in the statement -- there are no data presented to suggest this is necessarily a specific effect of myeloid secreted HB-Egf on the epithelial cells.

As above, this is an excellent point, and we have amended the text (subsection "Myeloid cells are required for PanIN maintenance and progression") to avoid confounding correlation with causality.
